Background {#Sec1}
==========

Heart failure (HF) is a common clinical condition with high mortality and morbidity rates \[[@CR1]\]. Chronic obstructive pulmonary disease (COPD) frequently coexists with HF, leading to poor prognosis as well as diagnostic and therapeutic challenges \[[@CR2]\]-\[[@CR17]\]. Estimates of COPD prevalence in patients with HF vary substantially between 9% and 52% in earlier reports that relied on clinical data, disease codes, or self-reported COPD for establishing the diagnosis \[[@CR2]\]. Spirometry is considered to be the gold standard for the diagnosis of COPD \[[@CR18]\], but is unfortunately still underutilised \[[@CR19]\]. Studies that used spirometry have also reported varying prevalence rates of COPD (9 - 44%) depending on study design, population, and diagnostic criteria \[[@CR14]\]-\[[@CR17]\],\[[@CR20]\]-\[[@CR23]\]. Airway obstruction is a dynamic phenomenon in HF, as it may be present in congestive HF and may disappear with treatment of HF \[[@CR14]\]. Therefore, a careful timing and interpretation of pulmonary function tests (PFTs) is required to avoid misdiagnosis and inappropriate treatment \[[@CR2]\]. Ideally, serial PFTs should be used under stable conditions when clinically euvolemic to establish a valid diagnosis of COPD by confirming persistent airway obstruction. However, data on the need of serial pulmonary function measurements are scarce and even lacking in patients with stable chronic HF (CHF). It is therefore unknown whether a confirmatory spirometry is necessary for the correct diagnosis of COPD in patients with stable non-congested CHF.

The present study determined the prevalence of COPD in outpatients with stable CHF without pulmonary congestion using initial as well as confirmatory spirometry three months after treatment with tiotropium in patients with newly diagnosed COPD.

Methods {#Sec2}
=======

Study design and participants {#Sec3}
-----------------------------

All patients attending two outpatient cardiology departments of a large general hospital in The Netherlands were screened for inclusion in this prospective study between October 2009 and December 2010. In addition, existing patient lists were used to ensure that the majority of HF population had been examined for eligibility. Inclusion criteria were CHF \[[@CR1]\] with left ventricular ejection fraction (LVEF) \< 40%, New York Heart Association (NYHA) class I-IV, and age of ± 18 years. CHF was defined according to European Society of Cardiology guidelines \[[@CR1]\]. Echocardiography was performed in patients without a recent (≤6 months) echocardiography to confirm persisting left ventricular systolic dysfunction (LVSD). Patients were classified as having stable HF in the absence of hospitalization due to progression of HF within 3?months, change in diuretics within 1?month, 3% or more weight gain within 3?days, and more than 50% increase of N-terminal pro-B natriuretic peptide (NT-pro-BNP) within 1?month when the baseline NT-pro-BNP was 100 pmol/L or higher or more than 100 pmol/L increase of NT-pro-BNP within 1?month when baseline NT-pro-BNP was below 100 pmol/L \[[@CR24]\]. Pulmonary congestion was evaluated on standard posterior-anterior and lateral chest radiographs for the presence or absence of alveolar oedema, pleural effusion, Kerley-B lines, and/or the redistribution of pulmonary blood flow by independent radiologists who qualitatively assessed the chest radiographs with an overall clinical impression. We excluded patients who were not able to cooperate or undergo spirometry or who had asthma according to their medical chart. Other exclusion criteria were malignancy with a poor prognosis (survival \< 6?months) and participation in another cardiology study. Patients who had been hospitalized in the pulmonary department in the past six weeks were included six weeks after discharge to ensure that their pulmonary function was stable at the time of spirometry testing.

Measurements and data collection {#Sec4}
--------------------------------

At baseline, a first blood sample was taken for the measurement of NT-pro-BNP according to the standard methods used at the hospital laboratory. One month later, the participants visited the hospital for an interview with the investigator and several examinations, including height and weight measurement, spirometry, and a chest radiograph. In addition, a second blood sample (NT-pro-BNP) was taken to determine the stability of HF. The Minnesota Living with Heart Failure Questionnaire \[[@CR25]\], modified Medical Research Council dyspnoea scale \[[@CR26]\], and 10-point Borg score \[[@CR27]\] were used to evaluate quality of life, effect of breathlessness on daily activities, and dyspnoea at rest, respectively. Additional data were collected from medical records and personal interviews. Arterial blood gas analysis was carried out in patients with severe airway obstruction to determine whether they had chronic respiratory failure \[[@CR18]\].

Patients with newly diagnosed COPD were followed up three months after standard treatment for COPD with once-daily 18 μg tiotropium. A third blood sample (NT-pro-BNP) was taken and spirometry was repeated to confirm persistent airway obstruction characteristic of COPD and exclude asthma as much as possible. Thus only patients with persistent airway obstruction on three months of follow-up were classified as having COPD.

Spirometry testing {#Sec5}
------------------

Spirometry (MasterLab Pro; Jaeger; Würzburg, Germany) was performed by trained and certified operators using standard techniques and according to European Respiratory Society standards for acceptability and reproducibility \[[@CR28]\]. The reference values of the European Community for Coal and Steel were used \[[@CR28]\]. Subjects with airway obstruction underwent post-bronchodilator spirometry 30 minutes after inhalation of four doses of 100 μg aerosolised salbutamol and four doses of 20 μg aerosolised ipratropium via Volumatic spacer. Participants were instructed not to take bronchodilators 6?24 hours before the tests, depending on the type of bronchodilator used. At follow-up, salbutamol and ipratropium were used, as previously described, when patients discontinued the use of tiotropium \> 24 hours prior to spirometry. Care was taken to match the timing of the second spirometry testing to the first to reduce variations that may occur over a 24-hour period.

Definitions {#Sec6}
-----------

*COPD* was defined according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines as post-bronchodilator ratio of forced expiratory volume in one second to forced vital capacity (FEV~1~/FVC) \< 0.7 \[[@CR18]\]. *COPD severity staging* was determined on the basis of FEV~1~ percent predicted according to GOLD criteria: FEV~1~ ± 80% predicted (stage I, mild), 50% ± FEV~1~ \< 80% predicted (stage II, moderate), 30% ± FEV~1~ \< 50% predicted (stage III, severe), and FEV~1~ \< 30% predicted or FEV~1~ \< 50% predicted plus chronic respiratory failure (stage IV, very severe) \[[@CR18]\].

*Smoking status* was defined as never (\<100 cigarettes in a lifetime), former (≥3 months ago), or current smoker (\<3 months). *Smoking pack-years (PY)* were based only on the tobacco cigarette history and one PY was defined as smoking 20 cigarettes a day for 1 year.

*Dyspnoea* was defined as resting dyspnoea or dyspnoea at any level of exertion, *chronic cough* as cough ± 3 months prior to the study, *chronic sputum production* as regular production of sputum for ± 3 months in 2 consecutive years, and *aspecific bronchial hyperreactivity (ABHR)* as respiratory symptoms in response to perfumes, scent of baking or paint, fog, cold air, or temperature changes.

Ethical considerations {#Sec7}
----------------------

The study was approved by the regional Research Ethics Committee Arnhem-Nijmegen in The Netherlands (2009/101, NL27798.091.09, ClinicalTrials.gov Identifier NCT01429376) and complies with the Declaration of Helsinki. All participants gave written informed consent.

Statistical analysis {#Sec8}
--------------------

Descriptive data are presented as mean ± standard deviation (SD) or as number (%). Baseline characteristics of patients with and without COPD were compared using the independent t-test or Mann-Whitney U test for continuous variables and the chi-square or Fisher\'s exact test for categorical variables, as appropriate. Correlations between COPD and LVEF and between COPD and NT-pro-BNP were examined using the Pearson\'s and Spearman\'s correlation coefficient tests, respectively. Association between COPD and NYHA class was examined using the chi-square test. Statistical analyses were performed using the Statistical Package for Social Science (SPSS, version 15.0). All statistical tests were two-sided and a p-value \< 0.05 was considered significant.

Results {#Sec9}
=======

Patient characteristics {#Sec10}
-----------------------

After screening of the entire HF population, a cohort of 337 patients with CHF was initially enrolled in this study. Thirty-eight patients withdrew informed consent and 65 patients were excluded due to several other reasons as specified in Figure [1](#Fig1){ref-type="fig"}. The remaining 234 patients were finally included of whom 187 had stable CHF without signs of pulmonary congestion. The characteristics of these patients are shown in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Mean age and LVEF were 69 ± 10 years and 29 ± 7%, respectively, and 78% were men. The majority of patients (72%) had NYHA class II, while only 16% and 12% had NYHA class I and III/IV, respectively. Almost 60% had an ischaemic aetiology of HF. Other causes of HF were idiopathic (24%), hypertension (6%), valve disease (6%), tachycardiomyopathy (3%), and other (2%). Most patients were former or current smokers (83%) and reported symptoms of dyspnoea (82%). Other respiratory symptoms were less common (cough 36%, sputum 23%, ABHR 29%). The patients received optimised, individually tailored drug treatment as maintenance therapy for their CHF.Figure 1**Flow-diagram of screening and final inclusion of study participants.** CHF, chronic heart failure; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; PFTs, pulmonary function tests.

###### 

**Characteristics of patients with and without COPD based on spirometry**

                            All (n = 187)   No COPD (n = 127)   COPD (n = 60)   P-value
  ------------------------- --------------- ------------------- --------------- ---------
  Age, years                69 ± 10         68 ± 11             70 ± 9          0.173
  Male sex, n (%)           146 (78)        94 (74)             52 (87)         0.051
  BMI, kg/m^2^              28 ± 5          29 ± 5              28 ± 5          0.064
  LVEF, %                   29 ± 7          29 ± 7              29 ± 7          0.401
  NYHA class, %                                                                 
  NYHA I-II                 164 (88)        114 (90)            50 (83)         0.211
  NYHA III-IV               23 (12)         13 (10)             10 (17)         0.211
  Ischaemic aetiology       110 (59)        71 (56)             39 (65)         0.238
  Smoking history, n (%)                                                        0.008
  Non-smoker                32 (17)         29 (23)             3 (5)           
  Current smoker            23 (12)         13 (10)             10 (17)         
  Former smoker             132 (71)        85 (67)             47 (78)         
  PY, years                 24 ± 24         21 ± 21             30 ± 28         0.016
  Co-morbidity, n (%)                                                           
  Myocardial infarction     109 (58)        71 (56)             38 (63)         0.336
  Atrial fibrillation       54 (29)         38 (30)             16 (27)         0.647
  Hypertension              80 (43)         51 (40)             29 (48)         0.291
  Diabetes mellitus         46 (25)         33 (26)             13 (22)         0.522
  PCI/CABG                  76 (41)         48 (38)             28 (47)         0.249
  CRT/ICD                   64 (34)         49 (39)             15 (25)         0.068
  Medication, n (%)                                                             
  ACE-I/ARB                 174 (93)        119 (94)            55 (92)         0.759
  β-blockers                172 (92)        116 (91)            56 (93)         0.778
  ± Selective               99 (58)         66 (57)             33 (59)         0.801
  ± Non-selective           73 (42)         50 (43)             23 (41)         0.801
  Diuretics                 159 (85)        107 (84)            52 (87)         0.666
  Aldosterone-antagonists   65 (35)         47 (37)             18 (30)         0.348
  ICS/OCS                   26 (14)         9 (7)               17 (28)         0.000
  β-agonists                29 (16)         7 (6)               22 (37)         0.000
  Anticholinergics          29 (16)         6 (5)               23 (38)         0.000

Data are presented as mean ± SD and number (%).

*Abbreviations:* *ACE-I/ARB* angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, *BMI* body mass index, *COPD* chronic obstructive pulmonary disease, *CRT/ICD* cardiac resynchronisation therapy/implantable cardioverter defibrillator, *ICS/OCS* inhalation/oral corticosteroids, *LVEF* left ventricular ejection fraction, *NYHA* New York Heart Association, *PCI/CABG* percutaneous coronary intervention/coronary artery bypass grafting, *PY* pack-years.

###### 

**Pulmonary symptoms and results of questionnaires, laboratory tests, and spirometry of patients with and without COPD based on spirometry**

                        All (n = 187)   No COPD (n = 127)   COPD (n = 60)   P-value
  --------------------- --------------- ------------------- --------------- ---------
  Symptoms, n (%)                                                           
  Cough                 67 (36)         38 (30)             29 (48)         0.014
  Sputum                43 (23)         26 (20)             17 (28)         0.233
  Dyspnoea              153 (82)        101 (80)            52 (87)         0.237
  ABHR                  55 (29)         29 (23)             26 (43)         0.004
  Questionnaires                                                            
  MLHFQ                 20 ± 17         19 ± 17             21 ± 18         0.568
  MRC                   1.5 ± 1.3       1.4 ± 1.3           1.7 ± 1.4       0.149
  Borg                  0.9 ± 1.2       0.8 ± 1.2           1.1 ± 1.3       0.036
  Laboratory data                                                           
  NT-pro-BNP1, pmol/L   201 ± 289       184 ± 273           236 ± 321       0.290
  NT-pro-BNP2, pmol/L   198 ± 308       179 ± 289           239 ± 345       0.250
  Spirometry                                                                
  FEV~1~, L             2.5 ± 0.8       2.7 ± 0.8           2.1 ± 0.7       0.000
  FEV~1~, % predicted   88 ± 21         96 ± 15             72 ± 22         0.000
  FVC, L                3.7 ± 1.0       3.7 ± 1.0           3.8 ± 1.0       0.699
  FVC, % predicted      102 ± 19        102 ± 17            101 ± 23        0.602
  FEV~1~/FVC, %         68 ± 11         74 ± 5              55 ± 10         0.000

Data are presented as mean ± SD. Only pre-bronchodilator lung function test results are presented to make comparison between groups possible. Laboratory data 1 and 2 refer to first (at baseline) and second (one month later) blood samples, respectively.

*Abbreviations:* *ABHR* aspecific bronchial hyperreactivity, *COPD* chronic obstructive pulmonary disease, *FEV*~*1*~*/FVC* ratio of forced expiratory volume in one second to forced vital capacity, *MLHFQ* Minnesota Living with Heart Failure Questionnaire, *MRC* modified Medical Research Council dyspnoea scale, *NT-pro-BNP* N-terminal pro-B natriuretic peptide.

COPD prevalence {#Sec11}
---------------

Initially, 61 (32.6%) CHF patients were diagnosed with COPD based on spirometry of whom 34 had a history of obstructive lung disease (OLD). Subsequently, 27 patients with newly diagnosed COPD were followed up three months after standard treatment for COPD. Two patients were lost to follow-up; one deceased and the other withdrew informed consent. One of the remaining 25 patients no longer had airway obstruction at follow-up, which was classified as mild upon initial assessment. Thus, COPD prevalence was 32.1% \[25.4-38.8%\] after three months of follow-up.

COPD prevalence tended to be higher in men than women (p = 0.051). It was also higher in former (36%) and current smokers (43%) than in non-smokers (9%), with no significant differences between current and former smokers (Figure [2](#Fig2){ref-type="fig"}A). None of the 9 patients aged between 31 and 50 years were diagnosed with COPD. COPD prevalence according to other age categories is shown in Figure [2](#Fig2){ref-type="fig"}B. Most patients had mild (46.7%) or moderate (40.0%) COPD, while only 8.3% and 5.0% had severe or very severe COPD, respectively.Figure 2**COPD prevalence and underdiagnosis according to (A) gender and smoking status, and (B) age categories.** COPD, chronic obstructive pulmonary disease; CS, current smokers; FS, former smokers; NS, non-smokers; OLD, obstructive lung disease. The grey parts of the bar represent the proportion of patients with COPD based on spirometry who did not have a history of OLD (i.e. previously underdiagnosed patients).

Underdiagnosis and overdiagnosis of COPD {#Sec12}
----------------------------------------

COPD was both over- and underdiagnosed (Figure [2](#Fig2){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). In terms of overdiagnosis, 32% (16/50) of patients with a history of OLD failed to demonstrate airway obstruction. In terms of underdiagnosis, 19% (26/137) of patients without a history of OLD were newly diagnosed with COPD based on spirometry. A history of OLD was defined as COPD (n = 43) or not further specified airway obstruction (n = 7) based on patient charts and/or general practitioner diagnosis.Table 3**Underdiagnosis and overdiagnosis of COPD**COPD (+)COPD (-)TotalHistory of OLD (+)34 (18.2)16 (8.6)50 (26.7)History of OLD (-)26 (13.9)111 (59.4)137 (73.3)Total60 (32.1)127 (67.9)187 (100)Data are presented as number (%).*Abbreviations:* *COPD* chronic obstructive pulmonary disease, *OLD* obstructive lung disease.

Determinants of COPD {#Sec13}
--------------------

Table [1](#Tab1){ref-type="table"} shows characteristics of patients with and without COPD based on spirometry. Pulmonary symptoms and the results of questionnaires, laboratory tests, and spirometry are presented in Table [2](#Tab2){ref-type="table"}. In univariate analysis patients with COPD were generally men who smoked more, used more pulmonary medication, had more respiratory symptoms of cough, ABHR, and dyspnoea according to Borg score, and tended to have a lower body mass index. In addition, they had worse lung function test results except for FVC. Other variables studied did not significantly vary between patients with and without COPD based on spirometry.

COPD was not associated with a higher NYHA class (p = 0.130). Also, there were no significant correlations between COPD and LVEF (p = 0.401) or NT-pro-BNP (p = 0.251).

Discussion {#Sec14}
==========

We observed a high prevalence (32.1%) of COPD in a well defined subgroup of stable CHF patients without pulmonary congestion who were recruited from two outpatient cardiology departments of a large general hospital. Using a three month follow-up spirometry to confirm initial diagnosis of de novo COPD did not change COPD prevalence significantly. The majority of patients remained obstructive at follow-up after three month of treatment with tiotropium.

Contrary to our results, initial airway obstruction was found in 19% of patients hospitalised for congestive systolic HF in the study of Brenner et al. \[[@CR14]\], but had resolved in 47% of these patients six months after discharge. This indicates that airway obstruction is a dynamic phenomenon in patients with HF, which often resolves after re-compensation. Therefore, a careful timing and interpretation of PFTs is required to avoid misdiagnosis and inappropriate treatment \[[@CR2]\]. Ideally, lung function measurements should be obtained under stable conditions when clinically euvolemic to establish a valid diagnosis of COPD. Indeed, the vast majority of patients, except for one (4%), with stable CHF without pulmonary congestion were reproducibly obstructed at follow-up in the current study. There was no indication of asthma in the patient who was not reproducibly obstructed at follow-up.

Our results support previous findings that COPD frequently coexists with HF \[[@CR15]\]-\[[@CR17]\],\[[@CR20]\]-\[[@CR22]\], but are in contrast to the study of Brenner et al. \[[@CR14]\] who found only 9% of patients with systolic HF to have concomitant COPD, probably explained by the high number of never smokers (45.6%) included in their study. Several factors might explain the high coexistence of these two diseases, including sharing of environmental (mainly smoking) or genetic risk factors, advanced age, systemic inflammation, and a relationship between a reduction in pulmonary and heart function \[[@CR2]\],\[[@CR5]\]-\[[@CR7]\],\[[@CR29]\]-\[[@CR33]\]. Also, COPD patients are at an increased risk of co-morbidities such as type 2 diabetes, which in turn are an important risk for cardiovascular disease \[[@CR30]\]. Furthermore, factors that increase stress on the cardiovascular system or precipitate arrhythmic events can also explain the association between COPD and cardiovascular disease, including hypoxemia, hyperinflation, hyperventilation, neurohumoral disturbances, increased work of breathing and oxygen consumption, pulmonary hypertension, and the use of pulmonary medication \[[@CR29]\],\[[@CR30]\],\[[@CR32]\],\[[@CR34]\]. Finally, other factors, such as oxidative stress, endothelial dysfunction, arterial stiffness, and connective tissue degradation have also been suggested to play a role \[[@CR32]\],\[[@CR34]\].

Since spirometry is still underutilized even in a tertiary-care facility \[[@CR19]\], it seems reasonable to consider routine spirometry testing in patients with CHF to diagnose or rule out COPD, a co-morbidity with important therapeutic and prognostic implications \[[@CR2]\],\[[@CR10]\]-\[[@CR16]\],\[[@CR22]\] which is still greatly under- and overdiagnosed as found in this study (19% and 32%, respectively). Indeed, diagnostic difficulties have been stressed before, including the overlap in signs, symptoms, and risk factors, the underuse of spirometry despite the fact that objective evidence of airway obstruction is mandatory for diagnosing COPD, and difficulties with interpreting spirometry results, especially in patients with decompensated HF \[[@CR2]\],\[[@CR4]\]-\[[@CR7]\],\[[@CR14]\]. This raises concerns regarding possible inappropriate treatment of COPD in an already vulnerable group of patients and as a result possible adverse impact on health and outcome.

Unfortunately, the current study was not large enough to find predictors of newly diagnosed COPD to make specific recommendations regarding which subgroup of patients should be tested. Also, it should be noted that a large proportion (69,2%) of newly diagnosed COPD patients had only mild airway obstruction that may represent a physiological decline of lung function with age instead of a disease \[[@CR35]\],\[[@CR36]\]. It is unknown whether an additional diagnosis and treatment of COPD in these patients would improve health outcomes and change their prognosis. This warrants further research to establish the effectiveness of screening of patients with CHF for COPD in terms of symptomatic relief and improvement of the outcome as well as cost-effectiveness of such a policy. Until then, spirometry could be used in CHF patients with pulmonary symptoms despite an adequate treatment for their HF, especially in the presence of risk factors for COPD, such as a smoking history of ± 10 PY and occupational exposures. Importantly, spirometry should be used when clinically euvolemic to avoid both misdiagnosis and inappropriate treatment of COPD \[[@CR2]\].

The current study has some limitations that deserve further discussion. It is important to realise that the results may not be applicable to all patients with CHF, since we did not include patients with preserved systolic function. The diagnosis of HF with preserved systolic function is challenging and particularly difficult to establish in patients with COPD \[[@CR5]\]. Thus, to avoid possible overestimation of COPD prevalence in our population, we only included patients with LVSD. Also, patients with more severe HF could have been under-represented in this study because of inability to participate. COPD prevalence may therefore have been somewhat underestimated. Likewise, there may be a recruitment bias in the cohort, given the refusal of 311 patients to provide informed consent. Finally, another limitation is the relatively small number of patients, particularly with COPD. However, included patient numbers are comparable to other recently published studies \[[@CR16]\],\[[@CR20]\]-\[[@CR22]\].

Despite these limitations, our findings have potential clinical implications. Our results indicate that confirmatory spirometry does not change a newly established diagnosis of COPD in the vast majority of patients with CHF, provided that PFTs are obtained during stable and non-congested conditions. The results also highlight the need for extensive use of spirometry to decrease the burden of undiagnosed or overdiagnosed COPD in patients with CHF. Evidently, the frequent underdiagnosis and overdiagnosis of COPD is not only a concern in the general population, but also in patients who are regularly monitored in outpatient cardiology clinics. Physicians should bear in mind that both diseases often coexist with important diagnostic and therapeutic difficulties and prognostic implications. Thus, both conditions must be simultaneously assessed and collaboration between cardiologists and pulmonologists is essential.

Conclusions {#Sec15}
===========

In conclusion, COPD is a frequent co-morbidity in patients with stable CHF without pulmonary congestion, but is often unrecognized or overdiagnosed. To avoid this and thus ensure adequate treatment of COPD in CHF, PFTs should be routinely obtained in a stable and non-congested condition. Under these conditions a confirmatory spirometry is unnecessary, as it does not change a newly established diagnosis of COPD in the vast majority of patients with CHF.

Authors' original submitted files for images {#Sec17}
============================================

Below are the links to the authors' original submitted files for images.Authors' original file for figure 1Authors' original file for figure 2

ABHR

:   Aspecific bronchial hyperreactivity

ACE-I

:   Angiotensin-converting enzyme inhibitor

ARB

:   Angiotensin receptor blocker

BMI

:   Body mass index

CABG

:   Coronary artery bypass grafting

CHF

:   Chronic HF

COPD

:   Chronic obstructive pulmonary disease

CRT/ICD

:   Cardiac resynchronisation therapy

CS

:   Current smokers

FS

:   Former smokers

FEV~1~/FVC

:   Ratio of forced expiratory volume in one second to forced vital capacity

GOLD

:   Global initiative for chronic obstructive lung disease

HF

:   Heart failure

ICD

:   Implantable cardioverter defibrillator

ICS/OCS

:   Inhalation/oral corticosteroids

LVEF

:   Left ventricular ejection fraction

LVSD

:   Left ventricular systolic dysfunction

MLHFQ

:   Minnesota living with heart failure questionnaire

MRC

:   Modified Medical Research Council dyspnoea scale

NS

:   Non-smokers

NT-pro-BNP

:   N-terminal pro-B natriuretic peptide

NYHA

:   New York Heart Association

OLD

:   Obstructive lung disease

PCI

:   Percutaneous coronary intervention

PFT

:   Pulmonary function tests

PY

:   Pack-years

SD

:   Standard deviation

SPSS

:   Statistical package for social science

**Competing interests**

The authors declare that they have no competing interests.

**Authors\' contributions**

AG contributed to the conception and design of the study, inclusion of participants, acquisition of the data, statistical analysis and interpretation of the data, and drafting of the manuscript. AG had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. FJJ, PNR, and YF contributed to the conception and design of the study, interpretation of the data, critical revision of the manuscript for important intellectual content, and supervision of the study. PJE contributed to the conception and design of the study, interpretation of the data, and critical revision of the manuscript for important intellectual content. FF contributed to the conception and design of the study, inclusion of participants, acquisition of the data, interpretation of the data, and critical revision of the manuscript for important intellectual content. PJPC contributed to the acquisition of the data and critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.

The authors would like to thank the participants in this study for their cooperation. We also would like to thank the nurse practitioners P.A. Ninaber, W.A.M. Janssen, W.H. van Zimmeren-Feijen, and heart failure nurse J.G. Froon-Elferink for their contribution to inclusion of participants and data collection. The authors owe much gratitude to the pulmonary function and clinical chemistry and haematology laboratories as well as the echocardiography and radiology departments for their assistance in data collection. Also, we would like to acknowledge biostatistician A.R.T. Donders for his contribution to statistical analysis. Finally, we would like to thank GlaxoSmithKline for supporting this study by an unrestricted grant. GlaxoSmithKline had no involvement in study design, data collection, data analysis, interpretation of data, writing of the manuscript, or in the decision to submit the manuscript for publication.

**Institutions at which the work was performed**

Department of Cardiology, Rijnstate Hospital, Wagnerlaan 55, 6815 AD, Arnhem, The Netherlands.

Department of Cardiology, Rijnstate Hospital, Hunneveldweg 14, 6903 ZN, Zevenaar, The Netherlands.
